Nine New Mexico women are among thousands nationally who have sued the makers of injectable contraception Depo-Provera.

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

Often, investors and Wall Street analysts focus on the short term and don't give enough thought to the long term.

In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...

Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. After winning a broader FDA label in metastatic castration-resistant prostate cancer (mCRPC) ...

Pfizer Inc. (NYSE: PFE) today announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA ® (lorlatinib, a third-generation ALK inhibitor, available in Europe ...

(ADCs) and multispecific antibodies for oncology. Under the terms of the mega-licensing and collaboration agreement, Pfizer and Suzhou, China-based Innovent agreed to codevelop and share costs for a ...

Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and ...

At his behest, the U.S. government took a nearly 10 percent stake in the chip manufacturer Intel in exchange for $8.9 billion ...

The absence of insider selling at Pfizer (PFE) after a sizable one-year rally is a data point retail investors should be weighing. The signal reflects the steady hand of professionals who see the ...

From Eli Lilly's David Ricks to Pfizer's Albert Bourla, the top five highest paid CEOs made a combined $157.8 million in 2025 ...

PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing ...